Aktienanalyse zu Vivos Therapeutics Inc (VVOS)VVOSVivos Therapeutics Inc

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Vivos Therapeutics is not a good buy right now due to significant financial instability and declining stock performance. The current price is $0.22, which has dropped 91.11% year-to-date. Additionally, the RSI is at 21.92, indicating the stock is oversold, but this does not guarantee a reversal. The company faces a widening net loss of $5.5 million in Q2 2026, alongside a cash position of only $1.8 million, which raises concerns about its ability to fund operations in the near term. The main risk is the potential for further equity dilution as analysts suggest significant reinforcement of the balance sheet is needed.